GRIFOLS ADR 1/2/EO-50 Market Cap ($4.21 Billion)
Market Cap & Net Worth: GRIFOLS ADR 1/2/EO-50 (G0F)
GRIFOLS ADR 1/2/EO-50 market cap. GRIFOLS ADR 1/2/EO-50 (F:G0F) has a market capitalization of $4.21 Billion (€3.60 Billion) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #3889 globally and #712 in its home market, demonstrating a -1.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GRIFOLS ADR 1/2/EO-50's stock price €4.26 by its total outstanding shares 844570736 (844.57 Million). Also see G0F cash flow conversion for how efficiently the company converts equity into cash flow.
GRIFOLS ADR 1/2/EO-50 Market Cap History (2022–2026)
GRIFOLS ADR 1/2/EO-50 market cap history from 2022 to 2026. Data shows change from $5.13 Billion to $4.99 Billion (-13.39% CAGR). Check GRIFOLS ADR 1/2/EO-50 share price for real-time trading data and today's change.
GRIFOLS ADR 1/2/EO-50 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GRIFOLS ADR 1/2/EO-50's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is GRIFOLS ADR 1/2/EO-50 growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.68x
GRIFOLS ADR 1/2/EO-50's market cap is 0.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
12.77x
GRIFOLS ADR 1/2/EO-50's market cap is 12.77 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $5.13 Billion | $6.06 Billion | $185.03 Million | 0.85x | 27.75x |
| 2023 | $7.31 Billion | $6.59 Billion | $42.00 Million | 1.11x | 173.97x |
| 2024 | $4.23 Billion | $7.21 Billion | $157.00 Million | 0.59x | 26.92x |
| 2025 | $5.13 Billion | $7.52 Billion | $402.00 Million | 0.68x | 12.77x |
Competitor Companies of G0F by Market Capitalization
Companies near GRIFOLS ADR 1/2/EO-50 in the global market cap rankings as of November 4, 2026. Also see GRIFOLS ADR 1/2/EO-50 balance sheet assets for a full breakdown of the balance sheet.
Key companies related to GRIFOLS ADR 1/2/EO-50 by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #12 globally with a market cap of $1.06 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #42 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #12 | Eli Lilly and Company | NYSE:LLY | $1.06 Trillion | $1410.99 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $270.56 |
| #42 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $288.84 |
Market Capitalization of GRIFOLS ADR 1/2/EO-50 (2022–2026)
Market capitalization of GRIFOLS ADR 1/2/EO-50 from 2022 to today. Between 2022 and today, GRIFOLS ADR 1/2/EO-50's market cap moved from $5.13 Billion to $ 4.99 Billion, with a yearly change of -13.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €4.99 Billion | -2.88% |
| 2025 | €5.13 Billion | +21.50% |
| 2024 | €4.23 Billion | -42.16% |
| 2023 | €7.31 Billion | +42.31% |
| 2022 | €5.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of GRIFOLS ADR 1/2/EO-50 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.21 Billion USD |
| MoneyControl | $4.21 Billion USD |
| MarketWatch | $4.21 Billion USD |
| marketcap.company | $4.21 Billion USD |
| Reuters | $4.21 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GRIFOLS ADR 1/2/EO-50
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more